# A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine

> **NCT04683224** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Vaxxinity, Inc.**

## Conditions studied

- Covid-19
- SARS-CoV-2
- Coronavirus

## Interventions

- **BIOLOGICAL:** UB-612
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04683224
- **Lead sponsor:** Vaxxinity, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-02-01
- **Primary completion:** 2023-03-22
- **Final completion:** 2023-03-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was withdrawn due to redesign of the protocol.
- **Last updated:** 2022-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04683224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04683224, "A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04683224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*